Telisotuzumab vedotin (ABBV-399)
Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.
Type of Molecule
BiologicTarget
cMetProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Non-Small Cell Lung Cancer | n/a |
Phase 3
|